Skip to main content

Advertisement

SpringerLink
Log in

Evolving Immunotherapy Approaches for Renal Cell Carcinoma

  • Genitourinary Cancers (DP Petrylak and JW Kim, Section Editors)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Metastatic renal cell carcinoma (mRCC) continues to be associated with high rates of morbidity and mortality. Renal cell carcinoma (RCC) is typically resistant to cytotoxic chemotherapy, and while targeted therapies have activity and prolong progression-free and overall survival, responses are usually not durable. Modulating the immune system with cytokine therapy, vaccine therapy, cell therapy, and checkpoint inhibitors offers hope of prolonged survival. Standard and emerging immune therapy approaches and combinations of immune therapies and other modalities are reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Ferlay J et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.

    Article  CAS  PubMed  Google Scholar 

  2. Fisher R, Gore M, Larkin J. Current and future systemic treatments for renal cell carcinoma. Semin Cancer Biol. 2013;23(1):38–45.

    Article  PubMed  Google Scholar 

  3. Gupta K et al. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008;34(3):193–205.

    Article  PubMed  Google Scholar 

  4. Rosenberg SA et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987;316(15):889–97.

    Article  CAS  PubMed  Google Scholar 

  5. Escudier B et al. Sequential therapy in renal cell carcinoma. Cancer. 2009;115(10 Suppl):2321–6.

    Article  CAS  PubMed  Google Scholar 

  6. Gleave ME et al. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med. 1998;338(18):1265–71.

    Article  CAS  PubMed  Google Scholar 

  7. Wierecky J et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res. 2006;66(11):5910–8.

    Article  CAS  PubMed  Google Scholar 

  8. Weinstock M, McDermott DF. Emerging role for novel immunotherapy agents in metastatic renal cell carcinoma: from bench to bedside. Am Soc Clin Oncol Educ Book, 2015. doi:10.14694/EdBook_AM.2015.35.e291

  9. Oliver RT, Nethersell AB, Bottomley JM. Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma. Br J Urol. 1989;63(2):128–31.

    Article  CAS  PubMed  Google Scholar 

  10. Fossa SD. Interferon in metastatic renal cell carcinoma. Semin Oncol. 2000;27(2):187–93.

    CAS  PubMed  Google Scholar 

  11. Mickisch GH et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358(9286):966–70.

    Article  CAS  PubMed  Google Scholar 

  12. Motzer RJ et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–24.

    Article  CAS  PubMed  Google Scholar 

  13. Floros T, Tarhini AA. Anticancer cytokines: biology and clinical effects of interferon-alpha2, interleukin (IL)-2, IL-15, IL-21, and IL-12. Semin Oncol. 2015;42(4):539–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Rosenberg SA et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA. 1994;271(12):907–13.

    Article  CAS  PubMed  Google Scholar 

  15. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000;6 Suppl 1:S55–7.

    PubMed  Google Scholar 

  16. McDermott DF et al. The high-dose aldesleukin “select” trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2015;21(3):561–8.

    Article  CAS  PubMed  Google Scholar 

  17. Motzer RJ et al. Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma. Clin Genitourin Cancer. 2009;7(1):28–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Ryan CW et al. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol. 2007;25(22):3296–301.

    Article  CAS  PubMed  Google Scholar 

  19. Escudier B et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605):2103–11.

    Article  PubMed  Google Scholar 

  20. Rini BI et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008;26(33):5422–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Escudier B et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010;28(13):2144–50.

    Article  CAS  PubMed  Google Scholar 

  22. Rini BI et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010;28(13):2137–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Dandamudi UB et al. A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a cytokine working group (CWG) study. J Immunother. 2013;36(9):490–5.

    Article  CAS  PubMed  Google Scholar 

  24. Procopio G et al. Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. Br J Cancer. 2011;104(8):1256–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Procopio G et al. Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial. Annals of Oncology, 2013

  26. McDermott DF et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23(1):133–41.

    Article  CAS  PubMed  Google Scholar 

  27. Rosenberg SA et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313(23):1485–92.

    Article  CAS  PubMed  Google Scholar 

  28. Rosenberg SA et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst. 1993;85(8):622–32.

    Article  CAS  PubMed  Google Scholar 

  29. Tomita Y et al. Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: long-term results. Int J Urol. 1998;5(1):16–21.

    Article  CAS  PubMed  Google Scholar 

  30. Wersall P, Mellstedt H. Increased LAK and T cell activation in responding renal cell carcinoma patients after low dose cyclophosphamide, IL-2 and alpha-IFN. Med Oncol. 1995;12(2):69–77.

    Article  CAS  PubMed  Google Scholar 

  31. Thompson JA et al. Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells. Cancer Res. 1989;49(1):235–40.

    CAS  PubMed  Google Scholar 

  32. Law TM et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer. 1995;76(5):824–32.

    Article  CAS  PubMed  Google Scholar 

  33. Bukowski RM et al. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma. Cancer Res. 1991;51(16):4199–205.

    CAS  PubMed  Google Scholar 

  34. Kradin R et al. Treatment of patients with advanced cancer using tumor-infiltrating lymphocytes and interleukin 2. Transplant Proc. 1988;20(2):336–8.

    CAS  PubMed  Google Scholar 

  35. Topalian SL et al. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol. 1988;6(5):839–53.

    CAS  PubMed  Google Scholar 

  36. Dillman R et al. Tumor-infiltrating lymphocytes and interleukin-2: dose and schedules of administration in the treatment of metastatic cancer. Cancer Biother Radiopharm. 2004;19(6):730–7.

    Article  CAS  PubMed  Google Scholar 

  37. Figlin RA et al. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol. 1999;17(8):2521–9.

    CAS  PubMed  Google Scholar 

  38. Goedegebuure PS et al. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study. J Clin Oncol. 1995;13(8):1939–49.

    CAS  PubMed  Google Scholar 

  39. Thiounn N et al. CD4 TIL (tumor infiltrating lymphocytes) induce complete response in patients treated with IL-2 (interleukin-2). Preliminary study. J Urol (Paris). 1994;100(4):185–8.

    CAS  Google Scholar 

  40. Liu L et al. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res. 2012;18(6):1751–9.

    Article  CAS  PubMed  Google Scholar 

  41. Engels B et al. Redirecting human T lymphocytes toward renal cell carcinoma specificity by retroviral transfer of T cell receptor genes. Hum Gene Ther. 2005;16(7):799–810.

    Article  CAS  PubMed  Google Scholar 

  42. Jiang HR et al. Combination of vaccination and chimeric receptor expressing T cells provides improved active therapy of tumors. J Immunol. 2006;177(7):4288–98.

    Article  CAS  PubMed  Google Scholar 

  43. Leisegang M et al. T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy. Clin Cancer Res. 2010;16(8):2333–43.

    Article  CAS  PubMed  Google Scholar 

  44. Amin A et al. Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): phase 2 study results. J Immunother Cancer. 2015;3:14.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Calderhead DM et al. Cytokine maturation followed by CD40L mRNA electroporation results in a clinically relevant dendritic cell product capable of inducing a potent proinflammatory CTL response. J Immunother. 2008;31(8):731–41.

    Article  CAS  PubMed  Google Scholar 

  46. DeBenedette MA et al. Priming of a novel subset of CD28+ rapidly expanding high-avidity effector memory CTL by post maturation electroporation-CD40L dendritic cells is IL-12 dependent. J Immunol. 2008;181(8):5296–305.

    Article  CAS  PubMed  Google Scholar 

  47. DeBenedette MA et al. Potency of mature CD40L RNA electroporated dendritic cells correlates with IL-12 secretion by tracking multifunctional CD8(+)/CD28(+) cytotoxic T-cell responses in vitro. J Immunother. 2011;34(1):45–57.

    Article  CAS  PubMed  Google Scholar 

  48. Reinhardt, C., et al., Results of a randomized phase II study investigating multipeptide vaccination with IMA901 in advanced renal cell carcinoma (RCC). ASCO Meeting Abstracts, 2010. 28(15_suppl): p. 4529.

  49. Amato RJ et al. Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res. 2010;16(22):5539–47.

    Article  CAS  PubMed  Google Scholar 

  50. Harrop R et al. MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients. Cancer Immunol Immunother. 2011;60(6):829–37.

    Article  CAS  PubMed  Google Scholar 

  51. Oudard S et al. A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings. Cancer Immunol Immunother. 2011;60(2):261–71.

    Article  CAS  PubMed  Google Scholar 

  52. Jocham D et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet. 2004;363(9409):594–9.

    Article  CAS  PubMed  Google Scholar 

  53. May M et al. Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting. Cancer Immunol Immunother. 2010;59(5):687–95.

    Article  PubMed  Google Scholar 

  54. Wood C et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet. 2008;372(9633):145–54.

    Article  CAS  PubMed  Google Scholar 

  55. Thumar JR, Kluger HM. Ipilimumab: a promising immunotherapy for melanoma. Oncology (Williston Park). 2010;24(14):1280–8.

    Google Scholar 

  56. Hodi FS et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Cozar JM et al. High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer. Hum Immunol. 2007;68(8):698–704.

    Article  CAS  PubMed  Google Scholar 

  58. Yang JC et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007;30(8):825–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Rini BI et al. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2011;117(4):758–67.

    Article  CAS  PubMed  Google Scholar 

  60. Zarour HM. Reversing T-cell dysfunction and exhaustion in cancer. Clin Cancer Res. 2016;22(8):1856–64.

    Article  CAS  PubMed  Google Scholar 

  61. Brahmer JR et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Topalian SL et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. McDermott DF. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol. 2015;33(18):2013–20. In treatment refractory advanced stage renal cell carcinoma nivolumab can produce durable responses with a manageable toxicity profile. This response can continue in some patients even after drug treatment is stopped.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Motzer RJ et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol. 2015;33(13):1430–7.

    Article  CAS  PubMed  Google Scholar 

  65. Motzer RJ. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13. Nivolumab is superior to everolimus in second- or third-line treatment of advanced clear cell renal cell carcinoma. Nivolumab is associated with higher rates of response and improved overall survival while producing fever grade 3 and 4 adverse events.

    Article  CAS  PubMed  Google Scholar 

  66. Brahmer JR et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. McDermott, DF et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study. J Clin Oncol. 2016. Atezolizumab, an anti PDL-1 antibody, shows antitumor activity in clear cell and non clear cell advanced renal cell carcinoma with an acceptable toxicity profile. Tumors with both positive and negative PDL-1 expression demonstrate response, though response rate is superior in PDL-1 expressing tumors.

  68. Sznol, M et al. Phase Ib evaluation of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) in patients (pts) with metastatic renal cell carcinoma (mRCC). ASCO Meeting Abstracts. 33(7_suppl): p. 410.

  69. Dudek AZ. Phase Ib study of pembrolizumab in combination with bevacizumab for the treatment of metastatic renal cell carcinoma: Big Ten Cancer Research Consortium BTCRC-GU14-003. ASCO Meeting Abstracts. 2016;34(2_suppl):559.

    Google Scholar 

  70. Wolchok JD et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122–33.

    Article  CAS  PubMed  Google Scholar 

  71. Hammers HJ et al. Expanded cohort results from CheckMate 016: a phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). ASCO Meeting Abstracts. 2015;33(15_suppl):4516.

    Google Scholar 

  72. Hammers HJ. Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). ASCO Meeting Abstracts. 2014;32(15_suppl):4504.

    Google Scholar 

  73. Atkins MB. Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): data from the KEYNOTE-029 phase 1 study. ASCO Meeting Abstracts. 2015;33(15_suppl):3009.

    Google Scholar 

  74. Choueiri TK. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): association of biomarkers with clinical outcomes. ASCO Meeting Abstracts. 2015;33(15_suppl):4500.

    Google Scholar 

  75. Herbst RS et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Jilaveanu LB et al. PD-L1 expression in clear cell renal cell carcinoma: an analysis of nephrectomy and sites of metastases. J Cancer. 2014;5(3):166–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Callea M. PD-L1 expression in primary clear cell renal cell carcinomas (ccRCCs) and their metastases. ASCO Meeting Abstracts. 2014;32(15_suppl):4585.

    Google Scholar 

  78. Baine MK et al. Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens. Oncotarget. 2015;6(28):24990–5002.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Medical Oncology, Department of Medicine, Yale Cancer Center, 333 Cedar Street, PO Box 208028, New Haven, 06510, CT, USA

    Susanna A. Curtis, Justine V. Cohen & Harriet M. Kluger

Authors
  1. Susanna A. Curtis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Justine V. Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Harriet M. Kluger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Harriet M. Kluger.

Ethics declarations

Conflict of Interest

Susanna A. Curtis declares that she has no conflict of interest.

Justine V. Cohen declares that she has no conflict of interest.

Harriet M. Kluger has received consulting fees or research funds from Merck, Regeneron Pharmaceuticals, Prometheus, and Alexion Pharmaceuticals.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Genitourinary Cancers

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Curtis, S.A., Cohen, J.V. & Kluger, H.M. Evolving Immunotherapy Approaches for Renal Cell Carcinoma. Curr Oncol Rep 18, 57 (2016). https://doi.org/10.1007/s11912-016-0542-9

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11912-016-0542-9

Keywords

Search

Navigation